1. Pink Sheet
  2. >>Legislation

BARDA Shake Up May Prompt Broad Review Of Politicization of Countermeasures Office

 
• By Sarah Karlin-Smith

Rick Bright is requesting an inspector general investigation into his removal as director of the Biomedical Advanced Research and Development, accusing the Trump administration of favoring politics over science when making COVID-19 funding decisions. 

White House

The recently transferred head of the US federal agency responsible for running key COVID-19 vaccine efforts with the drug industry said Wednesday that his abrupt demotion came after he cautioned against directing federal funding to coronavirus treatments that lacked scientific merit and pushed back against green-lighting the widespread use of two anti-malarial drugs championed by President Donald Trump.

Rick Bright who was removed Tuesday from his post as director of the Biomedical Advanced Research and Development Authority and Acting Deputy Assistant Secretary in the Office of the Assistant Secretary for Preparedness and Response 

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Legislation

More from Pink Sheet

Recent and Upcoming FDA Advisory Committee Meetings

 
• By Sue Sutter

Recent and upcoming US FDA advisory committee meetings and a summary of the topics covered.

UK Health Data Research Service Looks ‘Encouraging’ For Industry, But Implementation Details Will Be Key

 
• By Anabel Costa-Ferreira

Marcus Vass and Vladimir Murovec of international law firm Osborne Clarke tell the Pink Sheet what the government's planned HDRS might mean for industry, and how it compares with the European Health Data Space.

EU Health Data Space May Speed Up R&D Through Access To Multi-Omics & Clinical Record Data

 
• By Eliza Slawther

The European Health Data Space framework will allow companies to accelerate R&D processes and identify new molecular targets faster by facilitating centralized access to certain types of high-quality data, Finland’s Orion Pharma says.